Category: News

WaNPRC Director Dr. Deborah Fuller today welcomed Dr Raimon Duran-Struuck as a core faculty member of the Washington National Primate Research Center.  Dr Duran-Struuck is the Chair and a Professor in the UW Department of Comparative Medicine (DCM).

A passionate advocate for research animals, Dr Duran-Struuck says he’s inspired by the professionalism and care of people in research and the quality of our work with nonhuman primates. He says he’s “very excited” to contribute to advancing human and animal health.

“I’ve been working with NHPs for a long time, and I’ve always thought NHPs are an extremely valuable model to leverage our discoveries for safety and efficacy,” he said. “At end of the day what I tell my residents is that what we do here is to enhance discoveries. Think of a child w leukemia or a patient who depends on our discoveries. To me, that translates to being a small part of a big team that hopefully will be part of a big discovery.”

As an experienced lab animal veterinarian, researcher and instructor to medical students, Dr Duran-Struuck specializes in lab animal medicine and transplant immunology. He has published studies about immunotherapies for transplant rejection and Graft Versus Host Disease, which is a complication that can result from transplants of stem cells to treat blood disorders.

“I’m thrilled to welcome Raimon on board,” said Director Deborah Fuller.  “He brings a unique and highly impactful research program in transplant immunology that will further broaden the expertise of our world-renowned Gene Therapy and Regenerative Unit. As chair of DCM, Raimon also plays a crucial role in supporting all non-NHP animal research at UW and I very much value his expertise and efforts to support our common goals.”

Dr Duran-Struuck received his BS is biochemistry from Tufts University before earning his DVM there. He received his PhD in Immunology from the Universitat Autonoma de Barcelona. Prior to joining DCM, he was an Associate Professor in the Department of Pathobiology and a Director of Regulatory Affairs for University Lab Animal Resources at the University of Pennsylvania. Prior to that, he held research, clinical, and teaching positions at the Transplantation Biology Research Center at Massachusetts General Hospital, the Harvard University Department of Surgery, Tufts University, and Columbia University Medical Center.

Scientists and our public health infrastructure are critical for pandemic preparedness. Zika virus, a mosquito-borne disease with devastating effects on fetal brain development, continues to present a significant public health threat with far-reaching consequences for the U.S. economy and society. The virus gained global attention during the 2015-2018 epidemic, which was found to cause severe birth defects and disrupted birth rates and economies, across the Americas.

WaNPRC Associate Director of Research Kristina Adams Waldorf has been pivotal in identifying the threats posed by the Zika virus, and her findings are a perfect example of why research is essential to protect the U.S. public health and our economy. Dr Adams Waldorf’s research conclusively proved that Zika virus caused fetal brain injury, which reduced alternate theories and focused public health efforts.

Although the Zika virus epidemic began in Brazil, it wasn’t long before cases began spreading in Florida and Texas. This is why studying viruses in faraway places that can travel in the blood of an infected person and jump into mosquito populations in the U.S. is so important.

In early 2016, the news about Zika virus had reached mainstream newspapers in the U.S. Then, in the summer of 2016, the virus was found to be spreading locally in areas of Miami. Seemingly overnight, key voting populations and economic drivers in Florida were galvanized to support the scientific research for Zika virus.

“I was being contacted by real estate developers in Florida, who were seeing the value for housing cratering in areas of Miami near the Zika virus outbreak,” Adams Waldorf said. “Grandparents in Florida began donating to my research program, because their adult children were canceling visits to Florida based on fear of acquiring Zika virus.”

This fear was sufficient to cripple real estate and tourism in Florida, creating a crisis directly linking the virus with economic disruptions. A part of the economy that employs more than a million people and accounts for more than a billion dollars in economic activity had officials deeply worried. A decline in birth rates and an increase in medication abortion in Central and South America reflected the same worries of many American women and young families, who were trying to get pregnant.

The Zika virus outbreak also led to one extremely unusual incident in which the U.S. Central Intelligence Agency approached Dr. Adams Waldorf about the threat of bioterrorism from Zika.

“The CIA was concerned at the time that bad actors might be intentionally spreading Zika virus in the U.S. to create social and economic havoc in Florida and Texas,” Adams Waldorf said. “But this threat isn’t a complex international spy mystery. It’s about sick people getting on planes. This is why studying viruses that cause fetal birth defects is so important for our national security. They might seem unimportant and faraway, but they are literally in our backyard.”

The Adams Waldorf Lab is now studying the ways that fetal brain injury from Zika and other viruses can be detected during a pregnancy, which was a flash point for women who wanted to get pregnant or were currently pregnant during the Zika epidemic. Reassuring pregnant women that their pregnancies were healthy would have gone a long way to bolstering public health during this epidemic.

Government officials chose to spray areas of Miami, where Zika virus infected mosquitoes had been identified to eliminate the danger that it posed to Florida citizens. Fortunately, Zika virus was eliminated in Florida through these efforts, but the risk remains for a new epidemic.

Zika virus is now present in mosquitos and other animals throughout South and Central America, Dr. Adams Waldorf said. Once there are enough children in these populations that lack Zika virus immunity, because they weren’t alive or didn’t get infected in the 2015-2018 epidemic, there may be a new Zika virus epidemic.

The Adams Waldorf Laboratory is also identifying other viruses that could wreak havoc on public health and the economy. For example, the Oropouche virus is spread by midges and mosquitos and can be passed from a pregnant woman to their fetus. Oropouche has been associated with birth defects and stillbirths, similar to Zika. But the overall risk is still unknown and needs further study.

Studying birth defects caused by viruses is central to both public health and national security. But that can’t happen without researchers doing the basic science that will give public policymakers the information they need to make informed decisions.

A new paper co-authored by three WaNPRC researchers in Frontiers in Immunology indicates that people with HIV may be at greater risk for prolonged Zika virus (ZIKV) infections, and that people vulnerable to mosquito-borne illnesses like Zika would benefit from protections like vaccines. 

The paper, “Persistent innate immune dysfunction and ZIKV replication in the gastrointestinal tract during SIV infection in pigtail macaques,” suggests that people living with HIV may be at greater risk for prolonged Zika virus infections and that the virus stayed in the body longer. 

Dr. Megan O’Connor, Director Deb Fuller and former WaNPRC researcher and current affiliate Dr. Michael Gale contributed to the paper. The study looked at nonhuman primates (NHPs) co-infected with simian immunodeficiency virus (SIV) and Zika, the disease involved in a well-known outbreak in the Americas in 2015-2016 that infected tens of thousands of people and caused symptoms ranging from a rash and fever to microencephaly in babies (an abnormally small head), and even death. In the study NHPs had a harder time fighting off Zika, and the Zika virus stayed in their body longer, especially in places like the gut.  

They wrote: “Collectively, these findings uniquely suggest that untreated SIV infection may promote inflammatory cellular innate responses and create a state of persistent immune activation that contributes to prolonged ZIKV viremia and persistence in the gastrointestinal tract. Furthermore, these results suggest that people living with HIV and other immunocompromised individuals could be at higher risk for prolonged ZIKV infection, potentially extending the window of ZIKV transmission. These insights highlight the importance of including people living with HIV in strategies for deploying vaccines and treatments against ZIKV.” 

In other words, this indicates that people living with HIV, who have weaker immune systems, might have a harder time fighting off Zika, and it could stay in their bodies for a longer time. The researchers said this means public health officials need to make sure such people get treatments, such as vaccines, to help them fight off Zika more effectively. 

You can read the entire paper, here. 

Dr. Fuller was appointed director of WaNPRC in late last year. 

Dr O’Connor was appointed in February to the University of Washington faculty as Assistant Professor in the Department of Laboratory Medicine and Pathology.  She is a Core Scientist in the WaNPRC Infectious Disease and Translational Medicine Unit and focuses on HIV viral co-infections with the goal of improving treatment and vaccine strategies for people living with HIV and other immunocompromised people.

Chlamydia is one of the most widespread infectious diseases in the world, and it is remarkably difficult to prevent its spread.  However, Dr. Kevin Hybiske, microbiologist and professor at the University of Washington in infectious diseases, microbiology and global health, offers new hope in collaboration with the Washington National Primate Research Center.

In his lab, Dr. Hybiske is unraveling the complex ways this pathogen manipulates human cells to spread and evade the immune system. By understanding these mechanisms, his team aims to develop innovative therapies that could one day lead to better treatments and, ultimately, a reduction in the global health burden caused by this disease.

“Anecdotally, it’s probably one of the oldest bacterial pathogens of multicellular hosts,” Dr Hybiske said. “We study it because we still don’t understand the processes it uses to infect cells (and thus people), and we need to better understand that to so we can improve our ability to treat it.”

According to the World Health Organization, there were more than 128 million new cases of this sexually transmitted infection (STI) in 2020.  And before COVID, it was the most reported infection in the United States.

While Chlamydia can be easily treated with antibiotics, there is no preventative vaccine, and people infected with it often have no symptoms. These factors contribute to the high prevalence of Chlamydia in the population, disproportionally affecting women and people with limited access to medical screenings or treatment. If left undiagnosed and untreated, chlamydia can cause serious problems, including pelvic inflammatory disease and an increased risk of infertility and ectopic pregnancy.

Dr Hybiske’s lab is interested in studying the key steps involved with the development of the disease, in part, by creating “mutants” of chlamydia to learn how one mutant does its job of entering and exiting cells so that it can propagate.

“A big part of my lab is in the business of making Chlamydia mutants,” he said.  “We’re among the best in the world at that. We use this strategy to figure out what’s important” in the ways chlamydia infects and impacts humans.

“Microbiologists make mutants and figure out what processes they can no longer do and trace the facts to a gene that’s been disrupted. And that’s how you figure out how a pathogen does what it needs to do. Whether divide, or attach, or kill a host cell,” he said.  “Until about 10 years ago people who studied chlamydia couldn’t do that.”

A major hurdle to studying this pathogen is that, unlike some other bacteria, chlamydia requires a mammalian host and cannot be grown in a dish. Which is where WaNPRC comes in.

“I have had long professional relationships with investigators at UW who had established the chlamydia infection model in macaques. They’re the best in the world at it,” he said.

“This research is the kind of thing that can only be done in the circumstances that exist at WaNPRC because of the combination of collaborators, and the teams who care for the monkeys,” he said.  “This is the basic science we’ve only recently been able to do, and we’re among the best. We have small libraries of mutants that no one else has, and which we are eagerly hoping to test in relevant models. Our partnership with the WaNPRC allow us to experiment and test in ways that’s never been done.”

Hybiske and his team are keenly aware of the ethical considerations surrounding primate research and take steps to ensure that their work is responsible and beneficial. In a recent pilot study, Hybiske explored the vaccine potential of a new genetically attenuated mutant of Chlamydia and found that exposing monkeys to this vaccine strain was safe and led to immunity against challenge with a pathogenic Chlamydia strain. This type of responsible research is respectful of animal well-being and health and also has the potential to lead to promising advances for addressing human Chlamydia infections. He hopes to receive a grant to pursue this vaccine development further.

The World Health Organization is working to reduce the global burden of sexually transmitted infections like chlamydia, aiming for a 50% reduction in new cases of chlamydia by 2030. “My work slides into that,” Hybiske said.  “I am not someone who normally thinks about vaccine design, my work has mostly been focused on figuring out Chlamydia’s deep molecular secrets.”  And the secret could be connected to creating a mutant of chlamydia with special properties that could be beneficial in a vaccine.

“There’s a well-trod path to vaccine development, and we are at the beginning,” he said. “We’re doing the necessary next steps to see what happens. See where that takes it. Even if this strain doesn’t become a vaccine home run, we are poised to learn a great deal about the primate’s immune response to a Chlamydia vaccine, and this will certainly aid other people who are trying to make vaccines. If we are lucky, one of these vaccine candidates will work great and have an impact on public health.”